@misc{10481/87126,
year = {2021},
month = {9},
url = {https://hdl.handle.net/10481/87126},
abstract = {Aim: To develop and characterize bozepinib-loaded lipid-core nanocapsules (BZP-LNC+) as a potential
treatment for glioblastoma (GBM). Methods: Characterization of nanocapsules was performed by
diameter, polydispersity index, zeta potential, pH and encapsulation efficiency. GBM cell viability, cell
cycle and Annexin/PI were evaluated after BZP-LNC+ treatment. Synergism between BZP-LNC+ and
temozolomide (TMZ) was performed by CompuSyn software and confirmed in vitro and in vivo. Results:
BZP-LNC+ showed adequate particle sizes, positive zeta potential, narrow size distribution and high
encapsulation efficiency. BZP-LNC+ reduces GBM growth by inducing apoptosis. BZP-LNC+ and TMZ
showed synergistic effect in vitro and reduced the in vivo glioma growth by approximately 81%.
Conclusion: The present study provides proof-of-principle insights for the combination of these drugs
for GBM treatment.},
title = {Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma},
doi = {10.2217/nnm-2021-0164},
author = {Fraga Dias, Amanda de and Dallemole, Danieli Rosane and Bruinsmann, Franciele Aline and Lopes Silva, Luiz Fernando and Cruz López, Olga and Conejo-García, Ana and Oliveira Battastini, Ana María and Campos Rosa, Joaquín María and Stanisçaski Guterres, Silvia and Raffin Pohlmann, Adriana and Figueiró, Fabrício},
}